281 related articles for article (PubMed ID: 33781522)
1. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F
Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
4. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C
J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363
[TBL] [Abstract][Full Text] [Related]
6. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.
Johnsrud A; Ladha A; Muffly L; Shiraz P; Goldstein G; Osgood V; Shizuru JA; Johnston L; Arai S; Weng WK; Lowsky R; Rezvani AR; Meyer EH; Frank MJ; Negrin RS; Miklos DB; Sidana S
Transplant Cell Ther; 2021 Jul; 27(7):590.e1-590.e8. PubMed ID: 33915323
[TBL] [Abstract][Full Text] [Related]
7. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T
Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359
[TBL] [Abstract][Full Text] [Related]
8. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M
Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435
[TBL] [Abstract][Full Text] [Related]
9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
10. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
11. Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma.
Keklik M; Karakus E; Kaynar L; Akyol G; Guven ZT; Celik S; Baydar M; Sanlı N; Unal A; Cetin M
Transfus Apher Sci; 2020 Oct; 59(5):102844. PubMed ID: 32586769
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma].
Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
[TBL] [Abstract][Full Text] [Related]
15. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
16. Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma.
Bogucka-Fedorczuk A; Czyz A; Kalicińska E; Sawicki M; Laszkowska-Lewko M; Wicherska-Pawłowska K; Rybka J; Szeremet A; Prajs I; Szymczak D; Wróbel T
J Clin Apher; 2020 Aug; 35(4):246-254. PubMed ID: 32298020
[TBL] [Abstract][Full Text] [Related]
17. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
Antar A; Otrock ZK; Kharfan-Dabaja MA; Ghaddara HA; Kreidieh N; Mahfouz R; Bazarbachi A
Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
[TBL] [Abstract][Full Text] [Related]
18. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
[TBL] [Abstract][Full Text] [Related]
19. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Hagiwara S; Miwa A
Int J Hematol; 2018 May; 107(5):559-567. PubMed ID: 29388164
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
